Eli Lilly Stock News

Jake Van Naarden, who rules the oncology roost at Eli Lilly, is back in the dealmaking game. Monday morning he uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million $300 million in cash and $80 million for a premium equity deal to jump on board the biotechs

- Establishes co-development and co-commercialization agreement on Foghorn''s selective BRM program and an additional undisclosed program - Collaboration includes three additional discovery programs - Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share INDIANAPOLIS and CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), and Foghorn Therapeutics Inc. (NASDAQ: FHTX ), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn''s proprietary Gene Traffic Control® platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn''s selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn''s proprietary Gene Traffic Control platform. Under the terms of the agreement, Foghorn will receive upfront consideration of $300 million in cash for the collaboration agreement and an equity investment by Lilly of $80 million in Foghorn common shares at a price of $20 per share. "Oncogenic mutations in BRG1 impact a large population of cancer patients and we believe are best addressed therapeutically with a highly selective BRM inhibitor, though designing such a drug is a difficult chemistry challenge.

Wells Fargo & Company initiated coverage on shares of Eli Lilly and (NYSE:LLY) in a research note published on Wednesday morning, The Fly reports. The brokerage issued an equal weight rating and a $270.00 price objective on the stock. A number of other research firms have also weighed in on LLY. JPMorgan Chase & Co. []

Related Stocks: CMI , MSFT , AAPL , PSA ,

Vineet Gupta joined Eli Lilly in 2010 as Marketing Director for India, followed by a role as Corporate Affairs & Pricing Reimbursement and Access (PRA) Director in 2012.

Eli Lilly and Company (NYSE:LLY) Cantor Fitzgerald issued their FY2021 earnings per share (EPS) estimates for Eli Lilly and in a research note issued on Wednesday, December 8th. Cantor Fitzgerald analyst L. Chen expects that the company will earn $7.95 per share for the year. Eli Lilly and (NYSE:LLY) last released its earnings results [] The post Eli Lilly and Company Expected to Earn FY2021 Earnings of $7.95 Per Share (NYSE:LLY) appeared first on ETF Daily News .

Howard Capital Management Group LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 902 shares of the companys stock, valued at approximately $208,000. Other institutional investors have also []

Firm adds to holding in medical device manufacturer Check out PRIMECAP Management Stock Picks » Download GuruFolio Report of PRIMECAP Management (Updated on 12/09/2021) Related Stocks: LUNG , LLY , MSFT , BIIB , ADBE , TXN ,

Minot Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% in the 3rd quarter, Holdings Channel reports. The firm owned 2,580 shares of the companys stock after buying an additional 64 shares during the period. Minot Wealth Management LLCs holdings in Eli Lilly and were worth $596,000 at []

Foster Dykema Cabot & Co. Inc. MA raised its stake in Eli Lilly and Company (NYSE:LLY) by 71.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,053 shares of the company’s stock after acquiring an additional 1,269 shares during the quarter. Foster […]

(PR-inside.com) SHANGHAI, CHINA / ACCESSWIRE / December 10, 2021 / Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People''s Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities. The agreement will allow each company the opportunity to ..

Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co , Novo Nordisk and Sanofi , which control the market for insulin.

The global Social Anxiety Treatment market size is projected to reach US$ 13.9 Billion by 2027, at a CAGR of 3.3% during 2021-2027. The alarmingly high frequency of anxiety and sadness around the world has prompted medical experts to explore

Monument Capital Management boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,117 shares of the companys stock after buying an additional 45 shares during the period. []